July 5, 2012 / 5:41 PM / in 5 years

U.S. OKs Lupin generic of Pfizer nerve pain drug

(Reuters) - India’s Lupin Ltd said it won U.S. approval for a generic version of Pfizer Inc’s big-selling Lyrica nerve pain treatment.

A spokesman for Lupin said it has not yet launched its version of Lyrica, which is also known as pregabalin.

Lyrica tallied U.S. sales of about $1.8 billion for the year ended in March, Lupin said, citing data from IMS Health Inc.

Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below